FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592805105> ?p ?o ?g. }

• W2592805105 endingPage "474" @default.
• W2592805105 startingPage "474" @default.
• W2592805105 abstract "Abstract Background: Patients (pts) with rDLBCL not eligible for ASCT or experiencing relapse after ASCT have a low likelihood of cure. Single-drug maintenance after salvage therapy may be an attractive strategy to prolong survival in these pts. Lenalidomide (LEN) is a suitable candidate for long-lasting maintenance as it is an oral drug, active against DLBCL, that can be taken for years with an acceptable toxicity profile. Accordingly, we designed a multicentre phase II trial addressing LEN maintenance in pts with chemosensitive relapse of DLBCL not eligible for ASCT or experiencing relapse after ASCT (clinicaltrials.gov NCT00799513). Methods: HIV-neg pts (age ≥18 ys) with histologically-proven de novo or transformed DLBCL and relapsed disease responsive to conventional rituximab-containing salvage therapy were registered and treated with LEN 25 mg/day for 21 days out of 28, until lymphoma progression or unacceptable toxicity. Primary endpoint was 1-year progression-free survival (PFS). Simon's two-stage optimal design was used. To demonstrate a 1-yr PFS improvement from 30% (P0) to 50% (P1), 47 pts (one-sided; α 5%; β 80%) were needed. Maintenance would be considered effective if ≥19 pts were progression-free survivors at 1 yr. Cell of origin was assessed by NanoString Technology and Hans algorithm, and cereblon expression was assessed by immunohistochemistry. Results: 46 of 48 enrolled pts were assessable (median age 72 ys; range 34-86); 36 pts had de novo DLBCL, 10 had transformed DLBCL. All pts were previously treated with anthracycline- and rituximab-based combination, plus ASCT in 6 pts; the median TTP after the prior therapy was 16 months (range 3-121). Thirty-three pts were enrolled at 1st relapse, 13 at 2nd relapse; salvage therapy contained high doses of cytarabine or ifosfamide in two-thirds of cases, and response was complete in 26 pts and partial in 20. Most pts had unfavourable features: IPI ≥2 in 38 (83%) pts, advanced stage in 35 (76%), extranodal disease in 29 (63%), high LDH level in 21 (46%); 28 (61%) pts were older than 70 ys. At a median follow-up of 25 (range 6-87) months, 556 LEN courses were delivered, with an average of 12 courses/pt (range 3-41); 19 pts are still in treatment. LEN was well tolerated: with the exception of neutropenia, grade 3-4 toxicities were uncommon, occurring in ≤3% of delivered courses. Infections were rare, and well controlled with oral antibiotics (grade 1-2 in 8 courses; grade 3 in 3). LEN dose reduction was indicated in 23 pts (transient in 19), and was due to neutropenia (12), rash (7), diarrhoea (2), and neurotoxicity (2); LEN was discontinued in 6 of them. One (2%) pt died of acute toxicity (intestinal infarction) and one due to secondary myelodysplastic syndrome at 56 months of follow-up. Pts with HBV/HCV seropositivity (n=12) or prior ASCT (n=6) did not experience unexpected toxicity after >1 yr of treatment. At one year from trial registration, 28 pts were still progression free, which was significantly higher than the pre-determined efficacy threshold (n≥19). During the whole observation period, there were 21 events: progressive disease in 19 pts, death of toxicity in one, death while off therapy in one, with a 1-yr PFS (primary endpoint) of 70 ± 7%. The duration of response to LEN was longer than response duration after the prior treatment line in 27 (59%) pts, and was twice as long in 15 of them. The benefit of LEN maintenance was observed both in pts with de novo or transformed DLBCL. According to the Hans' algorithm, the 1-yr PFS was 64 ± 11% for GCB-DLBCL and 67 ± 11% for nonGCB-DLBCL (p= 0.67). Results using the Nanostring technique were consistent with the Hans' algorithm, with a concordance rate of 86%. There was no significant association between cereblon expression and PFS. Multivariate analysis confirmed that treatment at first relapse and a prior TTP ≥12 months were independently associated with better PFS. Overall, 33 (72%) pts are alive, with a 1- and 3-yr OS of 81 ± 6% and 71 ± 8%, respectively. Conclusions: With the limitations of a non-randomized design, this trial soundly promotes the use of LEN maintenance in pts with chemosensitive relapse of DLBCL not eligible for ASCT or experiencing relapse after ASCT. LEN was well tolerated in this elderly population, with survival benefit both in pts with de novo or transformed DLBCL, and both in pts with GCB- or nonGCB-DLBCL. These results warrant further investigation of immunomodulatory drugs as maintenance in these high-risk pts. Disclosures Spina: Teva Pharmaceuticals Industries: Membership on an entity's Board of Directors or advisory committees, Other: Speaker Fee; Mundipharma: Membership on an entity's Board of Directors or advisory committees, Other: Speaker Fee. Rusconi:Teva: Consultancy, Other: Congress attendance; Takeda: Consultancy; Janssen: Consultancy, Other: Congress attendance. Couto:Celgene: Employment, Equity Ownership. Ren:Celgene: Employment, Equity Ownership." @default.
• W2592805105 created "2017-03-16" @default.
• W2592805105 creator A5002203533 @default.
• W2592805105 creator A5003918671 @default.
• W2592805105 creator A5010313241 @default.
• W2592805105 creator A5016760892 @default.
• W2592805105 creator A5019077797 @default.
• W2592805105 creator A5031095551 @default.
• W2592805105 creator A5031900268 @default.
• W2592805105 creator A5036985315 @default.
• W2592805105 creator A5039006383 @default.
• W2592805105 creator A5039845542 @default.
• W2592805105 creator A5040899311 @default.
• W2592805105 creator A5042513487 @default.
• W2592805105 creator A5045518627 @default.
• W2592805105 creator A5049017377 @default.
• W2592805105 creator A5050568632 @default.
• W2592805105 creator A5053501418 @default.
• W2592805105 creator A5058371862 @default.
• W2592805105 creator A5061736991 @default.
• W2592805105 creator A5066814162 @default.
• W2592805105 creator A5081879832 @default.
• W2592805105 creator A5082819090 @default.
• W2592805105 creator A5085955672 @default.
• W2592805105 creator A5088914628 @default.
• W2592805105 date "2016-12-02" @default.
• W2592805105 modified "2023-09-30" @default.
• W2592805105 title "Lenalidomide Maintenance Significantly Improves Survival Figures in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Final Results of a Multicentre Phase II Trial" @default.
• W2592805105 doi "https://doi.org/10.1182/blood.v128.22.474.474" @default.
• W2592805105 hasPublicationYear "2016" @default.
• W2592805105 type Work @default.
• W2592805105 sameAs 2592805105 @default.
• W2592805105 citedByCount "1" @default.
• W2592805105 countsByYear W25928051052021 @default.
• W2592805105 crossrefType "journal-article" @default.
• W2592805105 hasAuthorship W2592805105A5002203533 @default.
• W2592805105 hasAuthorship W2592805105A5003918671 @default.
• W2592805105 hasAuthorship W2592805105A5010313241 @default.
• W2592805105 hasAuthorship W2592805105A5016760892 @default.
• W2592805105 hasAuthorship W2592805105A5019077797 @default.
• W2592805105 hasAuthorship W2592805105A5031095551 @default.
• W2592805105 hasAuthorship W2592805105A5031900268 @default.
• W2592805105 hasAuthorship W2592805105A5036985315 @default.
• W2592805105 hasAuthorship W2592805105A5039006383 @default.
• W2592805105 hasAuthorship W2592805105A5039845542 @default.
• W2592805105 hasAuthorship W2592805105A5040899311 @default.
• W2592805105 hasAuthorship W2592805105A5042513487 @default.
• W2592805105 hasAuthorship W2592805105A5045518627 @default.
• W2592805105 hasAuthorship W2592805105A5049017377 @default.
• W2592805105 hasAuthorship W2592805105A5050568632 @default.
• W2592805105 hasAuthorship W2592805105A5053501418 @default.
• W2592805105 hasAuthorship W2592805105A5058371862 @default.
• W2592805105 hasAuthorship W2592805105A5061736991 @default.
• W2592805105 hasAuthorship W2592805105A5066814162 @default.
• W2592805105 hasAuthorship W2592805105A5081879832 @default.
• W2592805105 hasAuthorship W2592805105A5082819090 @default.
• W2592805105 hasAuthorship W2592805105A5085955672 @default.
• W2592805105 hasAuthorship W2592805105A5088914628 @default.
• W2592805105 hasConcept C126322002 @default.
• W2592805105 hasConcept C141071460 @default.
• W2592805105 hasConcept C143998085 @default.
• W2592805105 hasConcept C203092338 @default.
• W2592805105 hasConcept C2776063141 @default.
• W2592805105 hasConcept C2776364478 @default.
• W2592805105 hasConcept C2776694085 @default.
• W2592805105 hasConcept C2778283404 @default.
• W2592805105 hasConcept C2778559949 @default.
• W2592805105 hasConcept C2779050716 @default.
• W2592805105 hasConcept C2779338263 @default.
• W2592805105 hasConcept C2780653079 @default.
• W2592805105 hasConcept C2780739268 @default.
• W2592805105 hasConcept C2780775027 @default.
• W2592805105 hasConcept C2911091166 @default.
• W2592805105 hasConcept C31760486 @default.
• W2592805105 hasConcept C535046627 @default.
• W2592805105 hasConcept C71924100 @default.
• W2592805105 hasConceptScore W2592805105C126322002 @default.
• W2592805105 hasConceptScore W2592805105C141071460 @default.
• W2592805105 hasConceptScore W2592805105C143998085 @default.
• W2592805105 hasConceptScore W2592805105C203092338 @default.
• W2592805105 hasConceptScore W2592805105C2776063141 @default.
• W2592805105 hasConceptScore W2592805105C2776364478 @default.
• W2592805105 hasConceptScore W2592805105C2776694085 @default.
• W2592805105 hasConceptScore W2592805105C2778283404 @default.
• W2592805105 hasConceptScore W2592805105C2778559949 @default.
• W2592805105 hasConceptScore W2592805105C2779050716 @default.
• W2592805105 hasConceptScore W2592805105C2779338263 @default.
• W2592805105 hasConceptScore W2592805105C2780653079 @default.
• W2592805105 hasConceptScore W2592805105C2780739268 @default.
• W2592805105 hasConceptScore W2592805105C2780775027 @default.
• W2592805105 hasConceptScore W2592805105C2911091166 @default.
• W2592805105 hasConceptScore W2592805105C31760486 @default.
• W2592805105 hasConceptScore W2592805105C535046627 @default.
• W2592805105 hasConceptScore W2592805105C71924100 @default.
• W2592805105 hasIssue "22" @default.
• W2592805105 hasLocation W25928051051 @default.
• W2592805105 hasOpenAccess W2592805105 @default.
• W2592805105 hasPrimaryLocation W25928051051 @default.

• next